Literature DB >> 8112201

A trial with diclofenac HEP plaster as topical treatment in minor sport injuries.

P Jenoure1, B Segesser, U Lühti, G Gremion.   

Abstract

Diclofenac HEP plaster was tested in an open study in the treatment of different traumatic sport and overload injuries, to confirm the results of efficacy and tolerability already shown in other clinical studies. A total of 101 patients were assigned to treatment and were eligible for the evaluation of results at the end of a 14-day treatment period. The average score of spontaneous pain, assessed by means of a verbal scale and a visual analogical scale, showed a clear difference in pain rating between the beginning and end of treatment. In general 60% pain reduction was observed. The difference in analgesic activity was already apparent on the 7th day of treatment (-28%). The reduction of pain was confirmed by changes in another subjective sign related to the injury: provoked pain. This symptom decreased in a manner comparable to spontaneous pain: 61% pain reduction after 2 weeks of treatment. Global assessment of efficacy, performed by the investigator at the end of treatment, showed the clear therapeutic activity of local treatment with diclofenac HEP plaster. Satisfactory results were obtained and only 18% of the patients (most of them with chronic and persistent pain) experienced ineffective pain relief at the end of the 2-week treatment. The beneficial effects of diclofenac HEP plaster on pain are confirmed by the patients' assessment, since almost identical scores were obtained. It is striking that the overall tolerance of diclofenac HEP plaster, applied topically twice a day for 2 weeks, was "good" or "excellent" in the 101 patients treated. Any side effect was reported on the patient's card and all the patients completed the study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112201

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  12 in total

1.  Diclofenac epolamine plus heparin plaster versus diclofenac epolamine plaster in mild to moderate ankle sprain: a randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase III trial.

Authors:  Cosimo Costantino; Jacek Kwarecki; Anatoly V Samokhin; Giuseppe Mautone; Stefano Rovati
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Targeted peripheral analgesics therapy for neuropathic pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 3.  Topical treatments for pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2004-08

Review 4.  A review of the use of topical analgesics for myofascial pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2002-10

5.  Diclofenac patches for postoperative shoulder pain.

Authors:  Lennard Funk; Rowena Umaar; Adeyinka Molajo
Journal:  Int J Shoulder Surg       Date:  2008-04

Review 6.  Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.

Authors:  B H McCarberg; C E Argoff
Journal:  Int J Clin Pract       Date:  2010-10       Impact factor: 2.503

7.  Skin permeability and pharmacokinetics of diclofenac epolamine administered by dermal patch in Yorkshire-Landrace pigs.

Authors:  Susanna Tse; Kendall D Powell; Stephen J Maclennan; Allan R Moorman; Craig Paterson; Rosonald R Bell
Journal:  J Pain Res       Date:  2012-10-23       Impact factor: 3.133

Review 8.  Topical agents for the treatment of chronic pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2006-02

Review 9.  Targeted topical peripheral analgesics in the management of pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2003-02

10.  Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch.

Authors:  David R Lionberger; Michael J Brennan
Journal:  J Pain Res       Date:  2010-11-10       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.